BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8683981)

  • 1. Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells.
    Nishimaki J; Miyazawa K; Gotoh A; Yoshikawa O; Ohyashiki K; Toyama K
    Leuk Res; 1996 May; 20(5):415-20. PubMed ID: 8683981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
    Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of proliferation in v-abl- and bcr-abl-transformed cells by a nucleoside analog.
    Cioé L; Mukhopadhyay S; Rovera G
    J Biol Chem; 1992 Nov; 267(31):22178-82. PubMed ID: 1331046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
    Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
    Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest.
    Clark SS; Perman SM; Sahin MB; Jenkins GJ; Elegbede JA
    Leukemia; 2002 Feb; 16(2):213-22. PubMed ID: 11840288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
    Mayerhofer M; Aichberger KJ; Florian S; Krauth MT; Hauswirth AW; Derdak S; Sperr WR; Esterbauer H; Wagner O; Marosi C; Pickl WF; Deininger M; Weisberg E; Druker BJ; Griffin JD; Sillaber C; Valent P
    FASEB J; 2005 Jun; 19(8):960-2. PubMed ID: 15784722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines.
    Sahin MB; Perman SM; Jenkins G; Clark SS
    Leukemia; 1999 Oct; 13(10):1581-91. PubMed ID: 10516760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.